Reflecting recent work in the

The production of peptides as active pharmaceutical ingredients (APIs) by recombinant technologies is of emerging interest. A reliable production platform, however, is still missing due to the inherent characteristics of peptides such as proteolytic sensitivity, aggregation, and cytotoxicity.

Numaswitch, a new technology solving present limitations. Numaswitch was successfully employed for the production of diverse peptides and small proteins varying in length,
physicochemical and functional characteristics, including Teriparatide, Linaclotide, human β- amyloid and Serum amyloid A3.

Additionally, the potential of Numaswitch for a cost-efficient commercial production is demonstrated yielding > 2 g Teriparatide per liter fermentation broth in a quality meeting API standard.